SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
One‐year experience of nucleic acid technology testing for human immunodeficiency virus Type 1, hepatitis C virus, and hepatitis B virus in Thai blood donations
5 references·10 citing·39 second hop
One‐year experience of nucleic acid technology testing for human immunodeficiency virus Type 1, hepatitis C virus, and hepatitis B virus in Thai blood donations (2009)One‐year experience of nucleic acid techn…Comparison of the analytical and operational performance of two viral nucleic acid test blood screening systems: Procleix Tigris and cobas s 201 (2008)Comparison of the analytical …A pilot study for screening blood donors in Taiwan by nucleic acid amplification technology: detecting occult hepatitis B virus infections and closing the serologic window period for hepatitis C virus (2008)A pilot study for screening b…Hepatitis B virus blood screening: unfinished agendas (2006)Hepatitis B virus blood scree…Detection of HIV-1 and HCV Infections among Antibody-Negative Blood Donors by Nucleic Acid–Amplification Testing (2004)Detection of HIV-1 and HCV In…Yield of HCV and HIV‐1 NAT after screening of 3.6 million blood donations in central Europe (2002)Yield of HCV and HIV‐1 NAT af…The impact of nucleic acid testing to detect human immunodeficiency virus, hepatitis C virus, and hepatitis B virus yields from a single blood center in China with 10-years review (2022)The impact of nucleic acid te…Blood Donation Screening of Transfusion-Transmissible Viral Infection Using Two Different Nucleic Acid Testing (NAT) Platforms: A Single Tertiary Care Oncology Centre Experience (2022)Blood Donation Screening of T…Automated Triplex (HBV, HCV and HIV) NAT Assay Systems for Blood Screening in India (2016)Automated Triplex (HBV, HCV a…Impact of nucleic acid amplification test on screening of blood donors in Northern Pakistan (2015)Impact of nucleic acid amplif…Estimating window period blood donations for human immunodeficiency virus T ype 1, hepatitis C virus, and hepatitis B virus by nucleic acid amplification testing in Southern P akistan (2014)Estimating window period bloo…Six-year pilot study on nucleic acid testing for blood donations in China (2013)Six-year pilot study on nucle…Evaluation of serological transfusion-transmitted viral diseases and mutliplex nucleic acid testing in malaysian blood donors (2013)Evaluation of serological tra…Reduction of the risk of transfusion‐transmitted viral infection by nucleic acid amplification testing in the Western Cape of South Africa: a 5‐year review (2012)Reduction of the risk of tran…Nucleic acid testing (NAT) in high prevalence–low resource settings (2010)Nucleic acid testing (NAT) in…BLOOD DONORS AND BLOOD COLLECTION: Web interface–supported transmission risk assessment and cost‐effectiveness analysis of postdonation screening: a global model applied to Ghana, Thailand, and the Netherlands (2009)BLOOD DONORS AND BLOOD COLLEC…A new strategy for estimating risks of transfusion‐transmitted viral infections based on rates of detection of recently infected donors (2005)Impact of individual‐donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa (2009)Infectivity of human immunodeficiency virus‐1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion (2009)Individual donor-nucleic acid testing for human immunodeficiency virus-1, hepatitis C virus and hepatitis B virus and its role in blood safety (2015)The infectious risks in blood transfusion as of today – A no black and white situation (2016)Systematic review of prevalence and risk factors of transfusion transmissible infections among blood donors, and blood safety improvements in Southern Africa (2023)Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing (2010)Blood transfusion and hepatitis: what does it take to prevent new infections? (2018)Transfusion Transmissible Infections: Maximizing Donor Surveillance (2018)Initial trends of individual donation nucleic acid testing in voluntary & replacement donors from a tertiary care centre in north India (2019)Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus‐1, hepatitis C virus, and hepatitis B virus (2008)International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009 (2011)Re-Entry Evaluation of Chinese Blood Donors with Unconfirmed Hepatitis B Screening Results (2022)Cost-benefit analysis of serological and nucleic acid testing for hepatitis B virus in blood donors in southern China (2024)Multicenter performance evaluation of a transcription‐mediated amplification assay for screening of human immunodeficiency virus‐1 RNA, hepatitis C virus RNA, and hepatitis B virus DNA in blood donations (2005)Trends in risk of transfusion-transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2003 and impact of nucleic acid testing (NAT) (2005)Blood donor screening with cobas s 201/cobas TaqScreen MPX under routine conditions at German Red Cross institutes (2009)Evaluation of two, commercial, multi‐dye, nucleic acid amplification technology tests, for HBV/HCV/HIV‐1/HIV‐2 and B19V/HAV, for screening blood and plasma for further manufacture (2012)Transfusion of HIV‐infected blood products despite highly sensitive nucleic acid testing (2019)NAT of the United States and Canadian blood supply (2000)Assessing the accuracy of three viral risk models in predicting the outcome of implementing HIV and HCV NAT donor screening in Australia and the implications for future HBV NAT (2002)The Risk of Transfusion-Transmitted Viral Infections (1996)The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection (1997)Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus, and HIV-1 in a blood-bank setting (1999)Nucleic acid amplification technology methods used in blood donor screening (2002)Window‐period human immunodeficiency virus transmission to two recipients by an adolescent blood donor (2004)World Development Report 1990. (1990)Health economics of blood transfusion safety – focus on sub-Saharan Africa (2009)Residual risk and waste in donated blood with pooled nucleic acid testing (2016)Robust Postdonation Blood Screening Under Prevalence Rate Uncertainty (2017)Predonation screening of blood donors with rapid tests: implementation and efficacy of a novel approach to blood safety in resource‐poor settings (2005)Trends in prevalence, incidence, and residual risk of major transfusion‐transmissible viral infections in United Arab Emirates blood donors: impact of individual‐donation nucleic acid testing, 2004 through 2009 (2012)Nucleic acid amplification testing in Indian blood banks: A review with perspectives (2017)Three-Year Experience in NAT Screening of Blood Donors for Transfusion Transmitted Viruses in Croatia (2017)Current prevalence and incidence of infectious disease markers and estimated window‐period risk in the American Red Cross blood donor population (2002)Prevention of transfusion-transmitted infections (2019)Multicenter evaluation of individual donor nucleic acid testing (NAT) for simultaneous detection of human immunodeficiency virus -1 & hepatitis B & C viruses in Indian blood donors. (2008)Residual risk of transfusion-transmitted infection with human immunodeficiency virus, hepatitis C virus, and hepatitis B virus in Korea from 2000 through 2010 (2012)Automated nucleic acid amplification testing in blood banks: An additional layer of blood safety (2015)
this work references cited by second hop

References

  • 2004Detection of HIV-1 and HCV Infections among Antibody-Negative Blood Donors by Nucleic Acid–Amplification Testing535 cited
  • 2006Hepatitis B virus blood screening: unfinished agendas94 cited
  • 2002Yield of HCV and HIV‐1 NAT after screening of 3.6 million blood donations in central Europe91 cited
  • 2008A pilot study for screening blood donors in Taiwan by nucleic acid amplification technology: detecting occult hepatitis B virus infections and closing the serologic window period for hepatitis C virus64 cited
  • 2008Comparison of the analytical and operational performance of two viral nucleic acid test blood screening systems: Procleix Tigris and cobas s 20152 cited

Cited by

  • 2010Nucleic acid testing (NAT) in high prevalence–low resource settings47 cited
  • 2012Reduction of the risk of transfusion‐transmitted viral infection by nucleic acid amplification testing in the Western Cape of South Africa: a 5‐year review39 cited
  • 2009BLOOD DONORS AND BLOOD COLLECTION: Web interface–supported transmission risk assessment and cost‐effectiveness analysis of postdonation screening: a global model applied to Ghana, Thailand, and the Netherlands31 cited
  • 2015Impact of nucleic acid amplification test on screening of blood donors in Northern Pakistan29 cited
  • 2013Six-year pilot study on nucleic acid testing for blood donations in China23 cited
  • 2022The impact of nucleic acid testing to detect human immunodeficiency virus, hepatitis C virus, and hepatitis B virus yields from a single blood center in China with 10-years review20 cited
  • 2014

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

Estimating window period blood donations for human immunodeficiency virus T ype 1, hepatitis C virus, and hepatitis B virus by nucleic acid amplification testing in Southern P akistan
19 cited
  • 2013Evaluation of serological transfusion-transmitted viral diseases and mutliplex nucleic acid testing in malaysian blood donors18 cited
  • 2016Automated Triplex (HBV, HCV and HIV) NAT Assay Systems for Blood Screening in India7 cited
  • 2022Blood Donation Screening of Transfusion-Transmissible Viral Infection Using Two Different Nucleic Acid Testing (NAT) Platforms: A Single Tertiary Care Oncology Centre Experience6 cited